Early Detection Initiative for Pancreatic Cancer

The Early Detection Initiative for Pancreatic Cancer is a multi-center prospective study to determine if algorithm-based screening in patients with glycemically defined new onset hyperglycemia and diabetes has the potential for earlier detection of pancreatic ductal adenocarcinoma.

Inclusion Criteria: * Patient must have given institutional consent for minimal risk studies. * Patient must be ≥50 and ≤85 years of age at the time of diagnosis \[index date Parameters of Diabetes Mellitus (PDM)\]. * Patient must have index weight and left-window weight values available in electronic medical record (EMR). * Patient must have hyperglycemia and/or diabetes as one of the following (all glycemic parameters, except for HbA1c, must be measured in an outpatient setting): A. Glycated hemoglobin (HbA1c) ≥ 6.5% OR B. Any (2) PDMs on consecutive (≤90 days between PDMs) or simultaneous testing: * Fasting Blood Glucose (FBG) ≥126 mg/dl * Glycated hemoglobin (HbA1c) ≥ 6.5% * Random Blood Glucose (RBG) ≥200 mg/dl * 2 hour Post Glucose (PG) ≥ 200mg (11.1 mmol/L) during oral glucose tolerance test (OGTT) OR C. Any one (1) PDM present followed by an anti- diabetes medication ≤90 days after the index PDM date * Patient must have ≥1 glycemic parameter measured in the past 91-548 days prior to the index PDM date (Left Window) without meeting inclusion criteria A, B, or C. * For Intervention Sites, patients must meet inclusion criteria A, B, or C ≤90 days prior to enrollment. Exclusion Criteria: * Patient has declined institutional consent for minimal risk studies. * Patient must not have any known past history of hyperglycemia and/or diabetes as defined by inclusion criteria A, B, or C \*Transient diabetes (e.g. gestational and steroid-induced) is not an exclusion. * Patient must not be on ongoing active treatment for cancer, and/or carry a current diagnosis of any cancer (except non-melanoma skin cancer). Non-invasive cancer of any organ (carcinoma-in-situ/high grade dysplasia) is not an exclusion. \*Ongoing work up for suspicion of pancreatic cancer is not an exclusion. * Patient must not have had a definitive diagnosis of pancreatic cancer prior to index PDM date. * Patient must not be on any anti-diabetes medications prior to index PDM date. * Patient must not be on chronic or acute use of steroid medications ≤90 days prior to the index PDM date. \*Allowed: Nasal, topical steroids, oral budesonide, ophthalmic * Patient must not have had an intra-articular steroid injection ≤ 7 days prior to the index PDM date. * Patient must have values available in the EMR to calculate the ENDPAC score.